Antibacterial effect of fucoidan from Sargassum wightii against the chosen human bacterial pathogens

Authors

  • Thangapandi Marudhupandi Centre of Advanced Study in Marine Biology Faculty of Marine Sciences Annamalai University Parangipettai - 608 502
  • Thipparamalai Thangappan Ajith Kumar Centre of Advanced Study in Marine Biology Faculty of Marine Sciences Annamalai University Parangipettai - 608 502

DOI:

https://doi.org/10.3329/icpj.v2i10.16408

Keywords:

Seaweed, polysaccharides, fucose, sulphate, antibacterial activity, brine shrimp toxicity

Abstract

The present study was aimed to evaluate the antibacterial capability of fucoidan from Sargassum wightii against the chosen human bacterial pathogens. The major chemical constituents of the extracted fucoidan were analyzed by biochemical methods. It showed that the extracted fucoidan contains 52.86 ± 0.64% of fucose and 29.26 ± 0.83% of sulphate. The antibacterial efficacy was performed by agar well diffusion, minimum inhibitory concentration (MIC) and minimum inhibitory concentration (MBC) method. The maximum antibacterial activity 18.6 ± 0.32 mm was obtained for Vibrio cholera and the minimum activity 8.6 ± 0.26 mm was obtained for Salmonella typhi. Result of this manifested the considerable antibacterial potentiality of fucoidan against human bacterial pathogens. Toxicity of fucoidan was evaluated by brine shrimp toxicity assay. No toxic effect was observed in fucoidan. Our study concluded that fucoidan might be used as natural and safe antibiotics in curing many bacterial diseases. Further study is required to get the better understanding of mode of action of fucoidan against the bacterial pathogens.

DOI: http://dx.doi.org/10.3329/icpj.v2i10.16408

International Current Pharmaceutical Journal, September 2013, 2(10): 156-158

Downloads

Download data is not yet available.
Abstract
1906
PDF
1314

Downloads

Published

2013-09-14

How to Cite

Marudhupandi, T., & Kumar, T. T. A. (2013). Antibacterial effect of fucoidan from Sargassum wightii against the chosen human bacterial pathogens. International Current Pharmaceutical Journal, 2(10), 156–158. https://doi.org/10.3329/icpj.v2i10.16408

Issue

Section

Original Articles